Logo 1 Logo 2

Investigational Drug Details

Drug ID: D270
Drug Name: Mesoridazine
Synonyms:
Type: small molecule
DrugBank ID: DB00933
DrugBank Description: A phenothiazine antipsychotic with effects similar to chlorpromazine.
PubChem ID: 4078
CasNo: 5588-33-0
Repositioning for NAFLD: Yes
SMILES: CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2
Structure:
InChiKey: SLVMESMUVMCQIY-UHFFFAOYSA-N
Molecular Weight: 386.574
DrugBank Targets: Dopamine D2 receptor; 5-hydroxytryptamine receptor 2A
DrugBank MoA: Based upon animal studies, mesoridazine, as with other phenothiazines, acts indirectly on reticular formation, whereby neuronal activity into reticular formation is reduced without affecting its intrinsic ability to activate the cerebral cortex. In addition, the phenothiazines exhibit at least part of their activities through depression of hypothalamic centers. Neurochemically, the phenothiazines are thought to exert their effects by a central adrenergic blocking action.
DrugBank Pharmacology: Mesoridazine, the besylate salt of a metabolite of thioridazine, is a phenothiazine tranquilizer. Pharmacological studies in laboratory animals have established that mesoridazine has a spectrum of pharmacodynamic actions typical of a major tranquilizer. In common with other tranquilizers it inhibits spontaneous motor activity in mice, prolongs thiopental and hexobarbital sleeping time in mice and produces spindles and block of arousal reaction in the EEG of rabbits. It is effective in blocking spinal reflexes in the cut and antagonizes d-amphetamine excitation and toxicity in grouped mice. It shows a moderate adrenergic blocking activity in vitro and in vivo and antagonizes 5-hydroxytryptamine in vivo. Intravenously administered, it lowers the blood pressure of anesthetized dogs. It has a weak antiacetylcholine effect in vitro.
DrugBank Indication: Used in the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses.
Targets:
Therapeutic Category:
Clinical Trial Progress:
Latest Progress: